Literature DB >> 20980808

Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung.

Hongdo Do, Renato Salemi, Carmel Murone, Paul L Mitchell, Alexander Dobrovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20980808     DOI： 10.4161/cc.9.21.13654

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  11 in total

Review 1.  EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Authors:  Yuxin Lin; Xian Wang; Hongchuan Jin
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

2.  Somatic activation of AKT3 causes hemispheric developmental brain malformations.

Authors:  Annapurna Poduri; Gilad D Evrony; Xuyu Cai; Princess Christina Elhosary; Rameen Beroukhim; Maria K Lehtinen; L Benjamin Hills; Erin L Heinzen; Anthony Hill; R Sean Hill; Brenda J Barry; Blaise F D Bourgeois; James J Riviello; A James Barkovich; Peter M Black; Keith L Ligon; Christopher A Walsh
Journal:  Neuron       Date:  2012-04-12       Impact factor: 17.173

3.  Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Authors:  Natasha Rekhtman; Paul K Paik; Maria E Arcila; Laura J Tafe; Geoffrey R Oxnard; Andre L Moreira; William D Travis; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

4.  Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase.

Authors:  Hongdo Do; Alexander Dobrovic
Journal:  Oncotarget       Date:  2012-05

5.  AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer.

Authors:  Donatella Malanga; Stefania Belmonte; Fabiana Colelli; Marzia Scarfò; Carmela De Marco; Duarte Mendes Oliveira; Teresa Mirante; Caterina Camastra; Monica Gagliardi; Antonia Rizzuto; Chiara Mignogna; Orlando Paciello; Serenella Papparella; Henrik Fagman; Giuseppe Viglietto
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

6.  Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.

Authors:  Yi Yu; Ronald E Savage; Sudharshan Eathiraj; Justin Meade; Michael J Wick; Terence Hall; Giovanni Abbadessa; Brian Schwartz
Journal:  PLoS One       Date:  2015-10-15       Impact factor: 3.240

7.  Mutant AKT1-E17K is oncogenic in lung epithelial cells.

Authors:  Carmela De Marco; Donatella Malanga; Nicola Rinaldo; Fernanda De Vita; Marianna Scrima; Sara Lovisa; Linda Fabris; Maria Vincenza Carriero; Renato Franco; Antonia Rizzuto; Gustavo Baldassarre; Giuseppe Viglietto
Journal:  Oncotarget       Date:  2015-11-24

Review 8.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

9.  Interaction-based discovery of functionally important genes in cancers.

Authors:  Dario Ghersi; Mona Singh
Journal:  Nucleic Acids Res       Date:  2013-12-19       Impact factor: 16.971

Review 10.  [Advances of molecular targeted therapy in squamous cell lung cancer].

Authors:  Li Ma; Shucai Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.